Short Term Rating on Illumina (ILMN)

Illumina (ILMN) : The consensus on Illumina (ILMN) based on 16 analyst recommendation on the company stock is 2.52, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 4 which endorses a Sell on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 10 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 1 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.

Illumina (ILMN) : Currently there are 14 street experts covering Illumina (ILMN) stock. The most bullish and bearish price target for the stock is $235 and $110 respectively for the short term. The average price target of all the analysts comes to $156.57. The estimated standard deviation from the target is $29.21.

Company shares have received an average consensus rating of Hold for the current week


Illumina (NASDAQ:ILMN): During Tuesdays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $141.06 and $141.06 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $149.41. The buying momentum continued till the end and the stock did not give up its gains. It closed at $148.99, notching a gain of 6.70% for the day. The total traded volume was 1,575,628 . The stock had closed at $139.64 on the previous day.

Illumina, Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems, consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms, reagent kits and scanning equipment. Its customers include genomic research centers, academic institutions, government laboratories, hospitals and reference laboratories, pharmaceutical, biotechnology, agrigenomics, commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research, including de novo sequencing, genetic variation analysis, epigenetics and targeted screening, among others. It also provides products and services for other life sciences applied markets, such as agrigenomics. It also offers Clarity Run Manager, Clarity LIMS Silver and Clarity LIMS Gold.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.